Yahoo
KOSDAQ - Delayed Quote KRW

JS Link, Inc. (127120.KQ)

18,230.00 -970.00 (-5.05%)
At close: October 30 at 3:30:30 PM GMT+9
Chart Range Bar
Loading chart for 127120.KQ
  • Previous Close 19,200.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 49,900.00
  • Volume 0
  • Avg. Volume 192,343
  • Market Cap (intraday) 633.335B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets. The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

jslink.co.kr

146

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

127120.KQ
2.13%
KOSPI Composite Index (^KS11)
35.99%

1-Year Return

127120.KQ
11.93%
KOSPI Composite Index (^KS11)
40.22%

3-Year Return

127120.KQ
420.11%
KOSPI Composite Index (^KS11)
148.02%

5-Year Return

127120.KQ
433.04%
KOSPI Composite Index (^KS11)
92.91%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.26%

  • Return on Assets (ttm)

    -8.26%

  • Return on Equity (ttm)

    -7.44%

  • Revenue (ttm)

    22.78B

  • Net Income Avi to Common (ttm)

    -5.3B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    72.23B

  • Total Debt/Equity (mrq)

    61.44%

  • Levered Free Cash Flow (ttm)

    -60.69B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: